Esophagus, Phase III
A Phase 3, Double-blind, Randomized Study of Zolbetuximab in Combination With Pembrolizumab and Chemotherapy (CAPOX or mFOLFOX6) in First-line Treatment of Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma in Participants Whose Tumors Are HER2-negative, Claudin (CLDN) 18.2-positive and Programmed Death-ligand 1 (PD-L1)-Positive
Volunteers
Health Professionals
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Andrea Brennan, PA
- Armand Russo, MD
- Caitlin Gallagher, APRN
- Clarice Grens, APRN
- Elizabeth Gaa, APRN
- Jacquelyne Gaddy, MD, MSc, MSCR
- Jeremy Kortmansky, MD
- Jill Lacy, MD
- Julia Marie DiBartolomeo, APRN
- Justin Persico, MD
- Megan Shulman, APRN
- Michael Cecchini, MD
- Neal Fischbach, MD
- Pamela L. Kunz, MD
- Sara Anastasio, APRN, RN
- Teresa White, APRN
- Thejal Srikumar, MD, MPH
- Virginia Syombathy, APRN
- Xiao Wang, MD
- Yifei Zhang, MD
- Last Updated03/20/2026
- Study IRB#2000039866